{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:46:39Z","timestamp":1786121199807,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72374011"],"award-info":[{"award-number":["72374011"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.autrev.2026.104099","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:32:42Z","timestamp":1780356762000},"page":"104099","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of treatment effects between ACR response criteria and target-based outcomes for contemporary rheumatoid arthritis drug approval trials: A meta-epidemiological study"],"prefix":"10.1016","volume":"25","author":[{"given":"Wengliang","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengchen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xindi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luwen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10055","key":"10.1016\/j.autrev.2026.104099_bb0005","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.autrev.2026.104099_bb0010","first-page":"531","article-title":"Choosing a core set of disease activity measures for rheumatoid arthritis clinical trials","volume":"20","author":"Felson","year":"1993","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104099_bb0015","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The committee on outcome measures in rheumatoid arthritis clinical trials","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2026.104099_bb0020","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American college of rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2026.104099_bb0025","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/art.1780330403","article-title":"Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The cooperative systematic studies of rheumatic diseases group","volume":"33","author":"Paulus","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104099_bb0030","series-title":"Guidance for Industry. Rheumatoid Arthritis: Developing Drug Products for Treatment","author":"Administration, U.F.A.D","year":"2013"},{"issue":"6","key":"10.1016\/j.autrev.2026.104099_bb0035","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s00296-011-2027-3","article-title":"Clinical trials in rheumatoid arthritis: a status report from the ClinicalTrials.gov website","volume":"32","author":"Paul","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2026.104099_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102405","article-title":"Precision medicine and management of rheumatoid arthritis","volume":"110","author":"Aletaha","year":"2020","journal-title":"J Autoimmun"},{"issue":"10","key":"10.1016\/j.autrev.2026.104099_bb0045","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/art.24123","article-title":"Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR\/ACR collaborative recommendations","volume":"59","author":"Aletaha","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104099_bb0050","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/ar4428","article-title":"The ACR20 and defining a threshold for response in rheumatic diseases: too much of a good thing","volume":"16","author":"Felson","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.autrev.2026.104099_bb0055","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res"},{"issue":"4","key":"10.1016\/j.autrev.2026.104099_bb0060","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104099_bb0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104099_bb0070","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/annrheumdis-2015-207526","article-title":"Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update","volume":"75","author":"Stoffer","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104099_bb0075","series-title":"Guideline on Clinical Investigation of Medicinal Products for the Treatment of Rheumatoid Arthritis","author":"Agency EM","year":"2018"},{"issue":"1","key":"10.1016\/j.autrev.2026.104099_bb0080","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1136\/ard-2023-224477","article-title":"Determination of the most appropriate ACR response definition for contemporary drug approval trials in rheumatoid arthritis","volume":"83","author":"Konzett","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2026.104099_bb0085","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/jcph.891","article-title":"Exposure-response modeling and power analysis of components of ACR response criteria in rheumatoid arthritis (part 1: binary model)","volume":"57","author":"Li","year":"2017","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104099_bb0090","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s13075-019-2005-9","article-title":"Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials","volume":"21","author":"Smolen","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.autrev.2026.104099_bb0095","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1136\/ard.2005.048975","article-title":"Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities","volume":"65","author":"Chung","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2026.104099_bb0100","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/ard.2008.092577","article-title":"Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data","volume":"68","author":"Dougados","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2026.104099_bb0105","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s43441-022-00492-z","article-title":"Examining endpoint concordance in clinical trials and real-world clinical practice to advance real-world evidence utilization","volume":"57","author":"Schaumberg","year":"2023","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"10.1016\/j.autrev.2026.104099_bb0110","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s43441-020-00193-5","article-title":"Bridging the gap between RCTs and RWE through endpoint selection","volume":"55","author":"LoCasale","year":"2021","journal-title":"Ther Innov Regul Sci"},{"issue":"9","key":"10.1016\/j.autrev.2026.104099_bb0115","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.recesp.2021.06.016","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"74","author":"Page","year":"2021","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.autrev.2026.104099_bb0120","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2026.104099_bb0125","unstructured":"Higgins JPTAD, Sterne JAC Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Chapter 8: Assessing risk of bias in included studies. Available from www.training.cochrane.org\/handbook."},{"issue":"11","key":"10.1016\/j.autrev.2026.104099_bb0130","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/sim.1184","article-title":"Statistical methods for assessing the influence of study characteristics on treatment effects in \u2018meta-epidemiological\u2019 research","volume":"21","author":"Sterne","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.autrev.2026.104099_bb0135","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/annrheumdis-2023-eular.4146","article-title":"POS0980\u00a0which ACR response definition should be used for disease activity claims in approval studies of rheumatoid arthritis? A systematic evaluation","volume":"82","author":"Konzett","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2026.104099_bb0140","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jbspin.2019.03.008","article-title":"Early clinical response and long-term radiographic progression in recent-onset rheumatoid arthritis: clinical remission within six months remains the treatment target","volume":"86","author":"Legrand","year":"2019","journal-title":"Joint Bone Spine"},{"issue":"11","key":"10.1016\/j.autrev.2026.104099_bb0145","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1093\/rheumatology\/keab153","article-title":"Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)","volume":"60","author":"Behrens","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.autrev.2026.104099_bb0150","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1080\/13696998.2019.1571498","article-title":"The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients","volume":"22","author":"Shahabi","year":"2019","journal-title":"J Med Econ"},{"issue":"10093","key":"10.1016\/j.autrev.2026.104099_bb0155","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.autrev.2026.104099_bb0160","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3899\/jrheum.141271","article-title":"A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate","volume":"42","author":"Pavelka","year":"2015","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104099_bb0165","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and safety of Upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2026.104099_bb0170","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/art.30129","article-title":"American College of Rheumatology\/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"63","author":"Felson","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.autrev.2026.104099_bb0175","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/art.23733","article-title":"The importance of reporting disease activity states in rheumatoid arthritis clinical trials","volume":"58","author":"Aletaha","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104099_bb0180","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ard-2022-223365","article-title":"Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Kerschbaumer","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"9602","key":"10.1016\/j.autrev.2026.104099_bb0185","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","article-title":"New therapies for treatment of rheumatoid arthritis","volume":"370","author":"Smolen","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.autrev.2026.104099_bb0190","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/RHU.0000000000001945","article-title":"The proportion of patients with rheumatoid arthritis achieving ACR20\/50\/70; consistent patterns of a 60\/40\/20 as demonstrated by a systematic review and meta-analysis","volume":"29","author":"Mokbel","year":"2023","journal-title":"J Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104099_bb0195","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/annrheumdis-2021-221807","article-title":"Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis","volume":"81","author":"Kerschbaumer","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104099_bb0200","author":"Health, C.A.F.D.A.T.I","year":"2019"},{"issue":"7","key":"10.1016\/j.autrev.2026.104099_bb0205","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1136\/annrheumdis-2016-209429","article-title":"Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"10139","key":"10.1016\/j.autrev.2026.104099_bb0210","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.autrev.2026.104099_bb0215","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheum"},{"issue":"10139","key":"10.1016\/j.autrev.2026.104099_bb0220","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"issue":"10188","key":"10.1016\/j.autrev.2026.104099_bb0225","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T02:59:15Z","timestamp":1786071555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226001138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1568997226001138"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104099","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of treatment effects between ACR response criteria and target-based outcomes for contemporary rheumatoid arthritis drug approval trials: A meta-epidemiological study","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104099"}}